Mutant p53 Companion Diagnostic for DNA-Binding Reactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells evade apoptosis through suppression of p53 function, leading to uncontrolled proliferation and metastasis, and existing treatments fail to effectively reactivate mutant p53 to restore its tumor suppressor activity.
Innovation Solution
Small molecule compounds selectively bind to mutant p53, stabilizing the protein structure and restoring its DNA-binding activity, thereby activating downstream effectors to inhibit cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used to target p53 mutations, then general cancer treatment is provided, but the treatments fail to effectively reactivate mutant p53 to restore its tumor suppressor activity
Solution Approach 1:
The patent applies parameter changes by developing small molecule compounds that specifically alter the conformational state of mutant p53 proteins. These compounds shift the equilibrium between misfolded and folded states, changing the structural parameters of mutant p53 to restore its DNA-binding capability and tumor suppressor function without affecting wild-type p53.
Solution Approach 2:
The patent uses small molecule compounds as intermediary agents that mediate between mutant p53 and its functional state. These compounds act as molecular chaperones that bind to mutant p53, stabilize its folded conformation, and facilitate its interaction with DNA, thereby restoring tumor suppressor activity without directly modifying the p53 gene sequence.
2Reliability
If small molecule compounds are designed to bind mutant p53, then DNA-binding activity is restored, but selective targeting of mutant versus wild-type p53 must be maintained
Solution Approach 1:
The patent applies local quality by designing small molecule compounds that specifically recognize and bind to local structural features unique to mutant p53 conformations. The compounds target specific hydrophobic patches or structural motifs that are exposed or created only in mutant forms, allowing selective stabilization of mutant p53 without binding to wild-type p53, thus maintaining selectivity while restoring DNA-binding activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds enhance p53 mutant activity by up to 10,000-fold, inducing apoptosis, cell cycle arrest, and senescence in cancer cells, providing a therapeutic approach for treating cancers with p53 mutations.
Implementation Method 1
Small molecule compounds selectively bind to mutant p53, stabilizing the protein structure and restoring its DNA-binding activity
Data Source
AI summary
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.